167 related articles for article (PubMed ID: 34695659)
1. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis.
Kim J; Shim MK; Cho YJ; Jeon S; Moon Y; Choi J; Kim J; Lee J; Lee JW; Kim K
Biomaterials; 2021 Dec; 279():121189. PubMed ID: 34695659
[TBL] [Abstract][Full Text] [Related]
2. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance.
Kim J; Shim MK; Yang S; Moon Y; Song S; Choi J; Kim J; Kim K
J Control Release; 2021 Feb; 330():920-932. PubMed ID: 33152391
[TBL] [Abstract][Full Text] [Related]
3. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
4. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity.
Shim MK; Yang S; Park J; Yoon JS; Kim J; Moon Y; Shim N; Jo M; Choi Y; Kim K
J Nanobiotechnology; 2022 Oct; 20(1):436. PubMed ID: 36195911
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity.
Tang L; Duan R; Zhong YJ; Firestone RA; Hong YP; Li JG; Xin YC; Wu HL; Li Y
Mol Cancer; 2014 Mar; 13():44. PubMed ID: 24588871
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy.
Shim MK; Moon Y; Yang S; Kim J; Cho H; Lim S; Yoon HY; Seong JK; Kim K
Biomaterials; 2020 Dec; 261():120347. PubMed ID: 32889501
[TBL] [Abstract][Full Text] [Related]
11. Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.
Xu S; Fan H; Yin L; Zhang J; Dong A; Deng L; Tang H
Eur J Pharm Biopharm; 2016 Jul; 104():251-9. PubMed ID: 27185379
[TBL] [Abstract][Full Text] [Related]
12. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.
Hunt H; Simón-Gracia L; Tobi A; Kotamraju VR; Sharma S; Nigul M; Sugahara KN; Ruoslahti E; Teesalu T
J Control Release; 2017 Aug; 260():142-153. PubMed ID: 28603028
[TBL] [Abstract][Full Text] [Related]
13. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
[TBL] [Abstract][Full Text] [Related]
14. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.
Lee SJ; Jeong YI; Park HK; Kang DH; Oh JS; Lee SG; Lee HC
Int J Nanomedicine; 2015; 10():5489-503. PubMed ID: 26357473
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).
Zhong YJ; Shao LH; Li Y
Int J Oncol; 2013 Feb; 42(2):373-83. PubMed ID: 23291656
[TBL] [Abstract][Full Text] [Related]
17. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
Tempfer CB; Giger-Pabst U; Seebacher V; Petersen M; Dogan A; Rezniczek GA
Gynecol Oncol; 2018 Jul; 150(1):23-30. PubMed ID: 29743140
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy.
Cho H; Shim MK; Yang S; Song S; Moon Y; Kim J; Byun Y; Ahn CH; Kim K
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056979
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy.
Cho H; Shim MK; Moon Y; Song S; Kim J; Choi J; Kim J; Lee Y; Park JY; Kim Y; Ahn CH; Kim MR; Yoon HY; Kim K
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297566
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M
Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]